Alexa B. Turke

发表

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2011, Science Translational Medicine.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Luca Toschi, A. Iafrate, P. Jänne, 2010, Cancer cell.

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Mari Mino-Kenudson, Keith T Flaherty, Erin M. Coffee, 2012, Cancer discovery.

A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2

N. Perrimon, J. Engelman, L. Cantley, 2016, Scientific Reports.

PIKing the Right Patient

J. Engelman, Alexa B. Turke, 2010, Clinical Cancer Research.

Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib

Erin M. Coffee, K. Flaherty, M. Mino‐Kenudson, 2012 .

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

Carlotta Costa, Carlos L Arteaga, John M Asara, 2012, Cancer research.

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.

P. Jänne, J. Engelman, L. Cantley, 2011, Cancer research.

Integrated Systems and Technologies Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI 3 K in Cancer

J. Engelman, L. Cantley, Alexa B. Turke, 2011 .

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

M. Rivera, D. Haber, J. Engelman, 2015, eLife.

Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Erin M. Coffee, K. Flaherty, M. Mino‐Kenudson, 2012 .

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

J. Engelman, Alexa B. Turke, J. Asara, 2012, Cancer research.

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.

P. Jänne, J. Engelman, L. Cantley, 2011, Cancer research.